Literature DB >> 21220376

Chronic migraine: classification and comparisons.

Z Katsarava1, A Manack, M-S Yoon, M Obermann, H Becker, P Dommes, C Turkel, R B Lipton, H C Diener.   

Abstract

OBJECTIVE: The objective of our study was to field test different chronic migraine (CM) criteria and compare CM epidemiological profiles, which include demographic, personal, and lifestyle characteristics, with high-frequency episodic migraine (HFEM) and low-frequency episodic migraine (LFEM).
METHODS: Questionnaires were mailed to a random sample of 18,000 18-65-year-olds in demographically diverse regions of Germany. The epidemiological data for the three classifications of CM, LFEM and HFEM were assessed using descriptive statistics, Pearson Chi-square, and analysis of variance tests.
RESULTS: Among 9350 respondents, CM_I was the most restrictive (N = 37, 0.4%), followed by CM_II (N = 45, 0.5%) and CM_III (N = 185, 2.0%). CM groups did not differ in distribution by age, gender, body mass index, education or smoking and alcohol consumption. Compared to those with LFEM and HFEM, those with CM (CM_III) had significantly different epidemiological profiles.
CONCLUSIONS: CM prevalence varies by case definition. The epidemiological profiles of the three CM groups are similar but differ significantly from those of HFEM and LFEM. Optimal definitions for clinical practice and epidemiological research require additional field testing.

Entities:  

Mesh:

Year:  2011        PMID: 21220376     DOI: 10.1177/0333102410383590

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  17 in total

1.  [Botulinum toxin type A for preventive treatment of chronic migraines].

Authors:  H Göbel; A Heinze
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

2.  [Botulinum toxin type A in the prophylactic treatment of chronic migraine].

Authors:  H Göbel; A Heinze
Journal:  Schmerz       Date:  2011-09       Impact factor: 1.107

3.  Prevalence of cardiac right left shunts in migraine: a population-based case-control study.

Authors:  Michael Küper; Kasja Rabe; Dagny Holle; Irini Savidou; Peter Dommes; Markus Frings; Hans Christoph Diener; Zaza Katsarava
Journal:  Neurol Sci       Date:  2012-02-25       Impact factor: 3.307

4.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

Review 5.  Botulinum toxin in the management of chronic migraine: clinical evidence and experience.

Authors:  Claus M Escher; Lejla Paracka; Dirk Dressler; Katja Kollewe
Journal:  Ther Adv Neurol Disord       Date:  2016-11-16       Impact factor: 6.570

Review 6.  [Headache. Current status of research and treatment].

Authors:  A Straube; C Gaul
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

7.  Prevalence of medication overuse headache in an interdisciplinary pain clinic.

Authors:  Corinne Wanner Schmid; Konrad Maurer; Daniel M Schmid; Eli Alon; Donat R Spahn; Andreas R Gantenbein; Peter S Sandor
Journal:  J Headache Pain       Date:  2013-01-30       Impact factor: 7.277

8.  The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study.

Authors:  Sun-Young Kim; Sung-Pa Park
Journal:  J Headache Pain       Date:  2014-10-02       Impact factor: 7.277

Review 9.  Targeting TRP channels for novel migraine therapeutics.

Authors:  Gregory Dussor; J Yan; Jennifer Y Xie; Michael H Ossipov; David W Dodick; Frank Porreca
Journal:  ACS Chem Neurosci       Date:  2014-08-29       Impact factor: 4.418

10.  The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results.

Authors:  Aubrey Manack Adams; Daniel Serrano; Dawn C Buse; Michael L Reed; Valerie Marske; Kristina M Fanning; Richard B Lipton
Journal:  Cephalalgia       Date:  2014-10-10       Impact factor: 6.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.